Previous 10 | Next 10 |
Annovis Bio Inc. (NYSE American:ANVS) traded today at a new 52-week high of $100.65. This new high was reached on below average trading volume as 505,000 shares traded hands, while the average 30-day volume is approximately 2.4 million shares. In the past 52 weeks, Annovis Bio Inc. share...
The company's Bryostatin drug is likely to read out positive data in current phase 2, despite its checkered past. Its current market cap is extremely low compared to other companies in this space - suggesting significant upside. A Nasdaq up-listing provides a catalyst as volume is...
With all of the recent news around a new treatment for Alzheimer's disease (AD), the huge gains by smaller biotechs developing treatments can get lost. The excitement is understandable. There have been 130 failed attempts to bring an AD treatment to market since 1998. Now that the Food ...
When the Food and Drug Administration (FDA) approved Biogen 's (NASDAQ: BIIB) aducanumab -- now marketed as Aduhelm -- for treating Alzheimer's Disease, it marked the end of a long drought. There hadn't been a therapy approved for the disease since 2003. The drug will still have to ...
Biotechs are ready to march forcefully higher after a lengthy consolidation. Approval of Biogen's Alzheimer's treatment creates a bonanza for neurodegenerative-focused companies and the overall biotech sector. The lower bar set for approval poses risk for Biogen in the out years. ...
Berwyn, Pennsylvania--(Newsfile Corp. - June 10, 2021) - Annovis Bio, Inc. (NYSE American: ANVS), ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced its partici...
When a biotech stock heads to the moon after releasing data on one of its drug programs, sometimes the party is just getting started. And that might be exactly the case for Annovis Bio (NYSEMKT: ANVS) , a biotech that's trying to tackle Alzheimer's disease and other neurodegener...
Preliminary data shows ANVS401 protects some types of nerve cells from dying after being infected by gingipains, the virulence factors of P. gingivalis Berwyn, Pennsylvania--(Newsfile Corp. - June 8, 2021) - Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis" or the "Company"), a clinical-stag...
Berwyn, Pennsylvania--(Newsfile Corp. - June 3, 2021) - Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced CEO Maria L. ...
Healthcare faces an important decision as the Supreme Court decides on the Affordable Care Act. Biotechs face an important FDA decision on approval of an Alzheimer's treatment. Oncology companies get ready to present new data at the largest US oncology conference with potential fo...
News, Short Squeeze, Breakout and More Instantly...
Annovis Bio (NYSE: ANVS) , a late-stage, drug-platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), today announced the receipt of U.S. Patent No. 12,042,482. The patent ...
MALVERN, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’...
The new executive team includes Mark White, Alexander Morin, Hilda Maibach, and Blake Jensen These additions are pivotal as the company makes strides toward bringing flagship drug candidate buntanetap closer to New Drug Application (“NDA”) status and to market Annovis Bio (NYS...